ArticleFrontiers in endocrinology2017
Frequency and Significance of
Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Thyroid Nodules with Indeterminate FNAC According to the Italian Classification System: Prevalence, Rate of Operation, and Impact on Risk of Malignancy. An Updated Systematic Review and Meta-analysis.Endocrine pathology · 2022Pooled it
- Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.Thyroid : official journal of the American Thyroid Association · 2019Pooled it
- Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience.Endocrine pathology · 2026Article
- Review
- Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era.Endocrine-related cancer · 2024Article
- Comparative Cyto-Histological Genetic Profile in a Series of Differentiated Thyroid Carcinomas.Diagnostics (Basel, Switzerland) · 2024Article
- Diagnostic utility ofEXCLI journal · 2024Review
- BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review.Journal of clinical medicine · 2023Article
- Molecular testing in indeterminate thyroid nodules: an additional tool for clinical decision-making.Pathologica · 2023Review
- Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool.World journal of surgical oncology · 2023Article
- Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.International journal of molecular sciences · 2021Review
- Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules.BMC cancer · 2021Article
- Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [Diagnostics (Basel, Switzerland) · 2021Review
- Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer.Cancers · 2021Review
- Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.Cancers · 2021Article
- Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.International journal of molecular sciences · 2021Review
- Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer of thyroid: A genomic linkage study.Annals of medicine and surgery (2012) · 2020Article
- Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.Gland surgery · 2020Review
- Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.Annals of translational medicine · 2020Review
- RAS Subcellular Localization Inversely Regulates Thyroid Tumor Growth and Dissemination.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe management of thyroid nodules of indeterminate cytology is controversial. Our study aimed to establish the frequency and significance of
methods
results69/199 (35%) were malignant on histopathological review.
conclusionThe residual malignancy risk in mutation-negative nodes is 25%. These nodes still need to be resected, but mutation analysis could help to orient the appropriate surgical strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.